logo
Menu

This search function provides links to outputs produced by NIHR Innovation Observatory. These are briefing notes or reports on new or repurposed technologies. This search will not return all technologies currently in development as these outputs are produced as required for our stakeholders.

Innovation Observatory > Reports > Drugs > Esketamine (nasal spray) for major depressive disorder with imminent risk of suicide

< Back

Esketamine (nasal spray) for major depressive disorder with imminent risk of suicide

Drugs

Mental Health, Drug Abuse and Learning Difficulties

February 2019


Esketamine nasal spray is being developed as a treatment that could be given to people with depression with an imminent risk of suicide. Major depressive disorder (often called depression or major depression in UK) is a serious mood disorder that can impact all aspects of daily life. Symptoms can include low mood, weight changes, lack of energy, disturbed sleep, and suicidal intentions and thoughts. The time between suicidal thoughts and attempted suicide is often very short, and so there is a need for urgent intervention and treatment.
Esketamine is currently used as an anaesthetic given as an intravenous infusion but is being developed as a nasal spray in a lower dosage that has demonstrated rapid antidepressant effect with fewer side effects. Esketamine nasal spray has been shown to reduce suicidal thoughts within 2 hours of treatment, whilst standard antidepressants take 4-6 weeks to be fully effective. Esketamine nasal spray may offer an important and rapid treatment to bridge the gap between onset of acute symptoms of depression such as suicidal thoughts and the delay it takes for standard antidepressants to start working.

Innovation Observatory Voice 0

Leave a Reply

Your email address will not be published. Required fields are marked *

Post Comment

Download Full Article



 

Connect to the Innovation Observatory

Twitter

Load More Related Posts

Get Alerts